Sudden cardiac death (SCD) in young athletes is a rare and dramatic event. Initial consensus guidelines from 2005 recommend restriction from competitive sports for all athletes with hereditary cardiomyopathies and channelopathies, with very minor exceptions.[@R1]

The field has changed: new data support a new approach {#s1}
======================================================

After decades of a conservative sports cardiology approach, recent findings call these universal restrictions into question. First, data on the use of automatic external defibrillators (AEDs) for witnessed sudden cardiac arrest (SCA) in sports have been reassuring.[@R2] When SCA is properly recognised and an AED immediately available, survival from SCA during sport is largely possible.

Second, two reports, one focusing on long QT syndrome in athletes,[@R3] and another on catecholaminergic ventricular tachycardia,[@R4] have suggested that the risk of competition may be acceptable if athletes are well-informed and fully compliant with therapy. A recent task force of the American Heart Association and American College of Cardiology has suggested that competitive sports practice may be permissible in some athletes with channelopathies, assuming that appropriate precautionary measures are in place. Specifically, avoidance of exacerbating drugs, avoidance of dehydration, appropriate electrolyte replenishment (with drinks containing Mg^2+^ and K^+^) and establishment of an emergency action plan with staff trained in cardiopulmonary resuscitation and access to an AED.[@R5]

Third, in a recently analysis of 184 consecutive deaths in patients with hypertrophic cardiomyopathy referred to a single cardiac pathology centre, the authors observed that 81% of deaths occurred at rest, unrelated to exertion.[@R6] In most cases of sudden death on exertion, a diagnosis was missed during life. These data suggest that diagnosing these individuals before a final ventricular arrhythmia occurs is of utmost importance, as it may allow the implementation of effective preventive measures, such as implantable cardioverter defibrillators (ICDs).

Fourth, our understanding of athletes with ICDs has progressed from data provided by the ICD Sports Safety Registry. In this multicentre, multinational registry no major adverse events (tachyarrhythmic death, externally resuscitated tachyarrhythmia during or after sports or severe injury resulting from arrhythmia-related syncope or shock during sports) were observed, suggesting that athletes can take part in sports without serious injury or failure of the ICD to terminate the arrhythmia.[@R7]

After following the trajectory of thousands of disqualified athletes over the years, we now realise that we lacked knowledge about the natural history of these disease entities and that old recommendations[@R1] were overcautious, as competitive sports might, after all, not cause a major cardiovascular event in all these individuals.

This understanding should prompt us to shift to a more balanced, but still cautious, approach when dealing with potential disqualification decisions in athletes with identified cardiac disorders.

Time for athlete empowerment {#s2}
============================

Over the past few decades, medicine in general has become more open to enabling the participation of patients in decisions about the diagnosis and treatment of their conditions, a concept known as 'empowerment', which is being implemented more widely.[@R8] A step forward with regard to cardiac disorders includes empowerment and shared decision-making, with placement of the athlete in a central role for planning their future.

Accordingly, we believe that it is the responsibility of the physician to inform athletes about the disease, natural history, treatment options, areas of uncertainty, and to assist them in making their decision based on their own values, and the underlying estimated risk of SCD. Can we deny these athletes the right to expose themselves to a small and uncertain risk that can be substantially reduced in most circumstances by AEDs, ICDs or medication, while we accept the risks of death or traumatic brain injury in motor sports and contact sports such as boxing/kick boxing, American football and rugby?

Cardiac disorders and contractual issues {#s3}
========================================

A special situation occurs for team physicians. Even though physicians employed by teams should still have the same empowering approach and obligations towards the athlete/patient, additional complexity and ethical issues arise when treating athletes finalising a financial contract. The team physician is obliged in his/her role to provide information to the team management about the athlete's health status. Accordingly, management may be concerned about the risk of SCD and the effect on their club, the possibility of disease progression such that the athlete needs to abandon sports, or the potential impact on the transfer fee if trying to negotiate with another club. If this occurs and the club aborts the signing of a contract, assuming the athlete is willing to compete, he/she will have to find a sports club who accepts the potential risks of the cardiac problem. It is ultimately up to the management to decide whether or not they accept hiring of the athlete. However, it should be up to the athlete---not the physician---whether they want to compete after being informed of the risk.

In conclusion, we believe this emerging evidence indicates that for many cardiac conditions the time has now come for sports cardiologists and team physicians to abandon a paternalistic approach and involve athletes in the decision-making process. After all, it is their lives and goals we are deciding, and to a certain point this can be considered a matter of free will and human rights. This should ideally be formalised in an informed consent process between the physician, athlete and sports team, outlining the known and unknown risks and recording that the athlete is making a fully informed decision to compete.
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